1.   Moll S, Desmouliere A, Moeller MJ, Pache JC, Badi L, Arcadu F, et al. DDR1 role in fibrosis and its pharmacological targeting. Biochim Biophys Acta Mol Cell Res. 2019.

2.   Wang H, Lo WT, Vujicic Zagar A, Gulluni F, Lehmann M, Scapozza L, et al. Autoregulation of Class II Alpha PI3K Activity by Its Lipid-Binding PX-C2 Domain Module. Mol Cell. 2018;71(2):343-51 e4.

3.   Trofimov V, Kicka S, Mucaria S, Hanna N, Ramon-Olayo F, Del Peral LV, et al. Antimycobacterial drug discovery using Mycobacteria-infected amoebae identifies anti-infectives and new molecular targets. Sci Rep. 2018;8(1):3939.

4.   Mukherjee B, Tessaro F, Vahokoski J, Kursula I, Marq JB, Scapozza L, et al. Modeling and resistant alleles explain the selectivity of antimalarial compound 49c towards apicomplexan aspartyl proteases. EMBO J. 2018;37(7).

5.   Gayi E, Neff LA, Massana Munoz X, Ismail HM, Sierra M, Mercier T, et al. Tamoxifen prolongs survival and alleviates symptoms in mice with fatal X-linked myotubular myopathy. Nat Commun. 2018;9(1):4848.

6.   Gayi E, Neff LA, Ismail HM, Ruegg UT, Scapozza L, Dorchies OM. Repurposing the Selective Oestrogen Receptor Modulator Tamoxifen for the Treatment of Duchenne Muscular Dystrophy. Chimia (Aarau). 2018;72(4):238-40.

7.   Garcia-Lopez A, Tessaro F, Jonker HRA, Wacker A, Richter C, Comte A, et al. Targeting RNA structure in SMN2 reverses spinal muscular atrophy molecular phenotypes. Nat Commun. 2018;9(1):2032.

8.   Festa BP, Berquez M, Gassama A, Amrein I, Ismail HM, Samardzija M, et al. OCRL Deficiency Impairs Endolysosomal Function in a Humanized Mouse Model for Lowe Syndrome and Dent Disease. Hum Mol Genet. 2018.

9.   Vujicic Zagar A, Scapozza L, Vadas O. Design and purification of active truncated phosphoinositide 3-kinase gamma protein constructs for structural studies. Protein Expr Purif. 2017;135:1-7.

10.  Ouertatani-Sakouhi H, Kicka S, Chiriano G, Harrison CF, Hilbi H, Scapozza L, et al. Inhibitors of Mycobacterium marinum virulence identified in a Dictyostelium discoideum host model. PLoS One. 2017;12(7):e0181121.

11.  Mologni L, Gambacorti-Passerini C, Goekjian P, Scapozza L. RET kinase inhibitors: a review of recent patents (2012-2015). Expert Opin Ther Pat. 2017;27(1):91-9.

12.  Lo WT, Vujicic Zagar A, Gerth F, Lehmann M, Puchkov D, Krylova O, et al. A Coincidence Detection Mechanism Controls PX-BAR Domain-Mediated Endocytic Membrane Remodeling via an Allosteric Structural Switch. Dev Cell. 2017;43(4):522-9 e4.

13.  Sotiriou SK, Kamileri I, Lugli N, Evangelou K, Da-Re C, Huber F, et al. Mammalian RAD52 Functions in Break-Induced Replication Repair of Collapsed DNA Replication Forks. Mol Cell. 2016;64(6):1127-34.

14.  Slepikas L, Chiriano G, Perozzo R, Tardy S, Kranjc A, Patthey-Vuadens O, et al. In Silico Driven Design and Synthesis of Rhodanine Derivatives as Novel Antibacterials Targeting the Enoyl Reductase InhA. J Med Chem. 2016;59(24):10917-28.

15.  Lauciello L, Lack G, Scapozza L, Perozzo R. A high yield optimized method for the production of acylated ACPs enabling the analysis of enzymes involved in P. falciparum fatty acid biosynthesis. Biochem Biophys Rep. 2016;8:310-7.

16.  Westermaier Y, Barril X, Scapozza L. Virtual screening: an in silico tool for interlacing the chemical universe with the proteome. Methods. 2015;71:44-57.

17.  Seredenina T, Chiriano G, Filippova A, Nayernia Z, Mahiout Z, Fioraso-Cartier L, et al. A subset of N-substituted phenothiazines inhibits NADPH oxidases. Free Radic Biol Med. 2015;86:239-49.

18.  Seebacher W, Wolkinger V, Faist J, Kaiser M, Brun R, Saf R, et al. Synthesis of 3-azabicyclo[3.2.2]nonanes and their antiprotozoal activities. Bioorg Med Chem Lett. 2015;25(7):1390-3.

19.  Neef AB, Pernot L, Schreier VN, Scapozza L, Luedtke NW. A Bioorthogonal Chemical Reporter of Viral Infection. Angew Chem Int Ed Engl. 2015;54(27):7911-4.

20.  Mologni L, Ceccon M, Pirola A, Chiriano G, Piazza R, Scapozza L, et al. NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922. Oncotarget. 2015;6(8):5720-34.

21.  Kaderli S, Viguier E, Watrelot-Virieux D, Roger T, Gurny R, Scapozza L, et al. Efficacy study of two novel hyaluronic acid-based formulations for viscosupplementation therapy in an early osteoarthrosic rabbit model. Eur J Pharm Biopharm. 2015;96:388-95.

22.  Kaderli S, Boulocher C, Pillet E, Watrelot-Virieux D, Rougemont AL, Roger T, et al. A novel biocompatible hyaluronic acid-chitosan hybrid hydrogel for osteoarthrosis therapy. Int J Pharm. 2015;483(1-2):158-68.

23.  Kaderli S, Boulocher C, Pillet E, Watrelot-Virieux D, Roger T, Viguier E, et al. A novel oxido-viscosifying Hyaluronic Acid-antioxidant conjugate for osteoarthritis therapy: biocompatibility assessments. Eur J Pharm Biopharm. 2015;90:70-9.

24.  Harrison CF, Kicka S, Kranjc A, Finsel I, Chiriano G, Ouertatani-Sakouhi H, et al. Adrenergic antagonists restrict replication of Legionella. Microbiology. 2015;161(7):1392-406.

25.  Harrison CF, Chiriano G, Finsel I, Manske C, Hoffmann C, Steiner B, et al. Amoebae-Based Screening Reveals a Novel Family of Compounds Restricting Intracellular Legionella pneumophila. ACS Infect Dis. 2015;1(7):327-38.

26.  De Andrade PB, Neff LA, Strosova MK, Arsenijevic D, Patthey-Vuadens O, Scapozza L, et al. Caloric restriction induces energy-sparing alterations in skeletal muscle contraction, fiber composition and local thyroid hormone metabolism that persist during catch-up fat upon refeeding. Front Physiol. 2015;6:254.

27.  Cwiek P, Leni Z, Salm F, Dimitrova V, Styp-Rekowska B, Chiriano G, et al. RNA interference screening identifies a novel role for PCTK1/CDK16 in medulloblastoma with c-Myc amplification. Oncotarget. 2015;6(1):116-29.

28.  Wang T, Bisson WH, Maser P, Scapozza L, Picard D. Differences in conformational dynamics between Plasmodium falciparum and human Hsp90 orthologues enable the structure-based discovery of pathogen-selective inhibitors. J Med Chem. 2014;57(6):2524-35.

29.  Tardy S, Orsato A, Mologni L, Bisson WH, Donadoni C, Gambacorti-Passerini C, et al. Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors. Bioorg Med Chem. 2014;22(4):1303-12.

30.  Monaco A, Michelin O, Prior J, Ruegg C, Scapozza L, Seimbille Y. Synthesis of a non-peptidic PET tracer designed for alpha5beta1 integrin receptor. J Labelled Comp Radiopharm. 2014;57(5):365-70.

31.  Lapteva M, Santer V, Mondon K, Patmanidis I, Chiriano G, Scapozza L, et al. Targeted cutaneous delivery of ciclosporin A using micellar nanocarriers and the possible role of inter-cluster regions as molecular transport pathways. J Control Release. 2014;196:9-18.

32.  Kicka S, Trofimov V, Harrison C, Ouertatani-Sakouhi H, McKinney J, Scapozza L, et al. Establishment and validation of whole-cell based fluorescence assays to identify anti-mycobacterial compounds using the Acanthamoeba castellanii-Mycobacterium marinum host-pathogen system. PLoS One. 2014;9(1):e87834.

33.  Ismail HM, Scapozza L, Ruegg UT, Dorchies OM. Diapocynin, a dimer of the NADPH oxidase inhibitor apocynin, reduces ROS production and prevents force loss in eccentrically contracting dystrophic muscle. PLoS One. 2014;9(10):e110708.

34.  Graven P, Tambalo M, Scapozza L, Perozzo R. Purine metabolite and energy charge analysis of Trypanosoma brucei cells in different growth phases using an optimized ion-pair RP-HPLC/UV for the quantification of adenine and guanine pools. Exp Parasitol. 2014;141:28-38.

35.  Westermaier Y, Veurink M, Riis-Johannessen T, Guinchard S, Gurny R, Scapozza L. Identification of aggregation breakers for bevacizumab (Avastin(R)) self-association through similarity searching and interaction studies. Eur J Pharm Biopharm. 2013;85(3 Pt A):773-80.

36.  Veurink M, Westermaier Y, Gurny R, Scapozza L. Breaking the aggregation of the monoclonal antibody bevacizumab (avastin(R)) by dexamethasone phosphate: insights from molecular modelling and asymmetrical flow field-flow fractionation. Pharm Res. 2013;30(4):1176-87.

37.  Tolomeo M, Roberti M, Scapozza L, Tarantelli C, Giacomini E, Titone L, et al. TTAS a new stilbene derivative that induces apoptosis in Leishmania infantum. Exp Parasitol. 2013;133(1):37-43.

38.  Pieretti S, Haanstra JR, Mazet M, Perozzo R, Bergamini C, Prati F, et al. Naphthoquinone derivatives exert their antitrypanosomal activity via a multi-target mechanism. PLoS Negl Trop Dis. 2013;7(1):e2012.

39.  Muller U, Ross TL, Ranadheera C, Slavik R, Muller A, Born M, et al. Synthesis and preclinical evaluation of a new C-6 alkylated pyrimidine derivative as a PET imaging agent for HSV1-tk gene expression. Am J Nucl Med Mol Imaging. 2013;3(1):71-84.

40.  Monaco A, Zoete V, Alghisi GC, Ruegg C, Michelin O, Prior J, et al. Synthesis and in vitro evaluation of a novel radioligand for alphavbeta3 integrin receptor imaging: [18F]FPPA-c(RGDfK). Bioorg Med Chem Lett. 2013;23(22):6068-72.

41.  Mescic A, Kristafor S, Novakovic I, Osmanovic A, Muller U, Zavrsnik D, et al. C-5 hydroxyethyl and hydroxypropyl acyclonucleosides as substrates for thymidine kinase of herpes simplex virus type 1 (HSV-1 TK): syntheses and biological evaluation. Molecules. 2013;18(5):5104-24.

42.  Lauciello L, Kappes B, Scapozza L, Perozzo R. Expression, purification and biochemical characterization of recombinant Ca-dependent protein kinase 2 of the malaria parasite Plasmodium falciparum. Protein Expr Purif. 2013;90(2):170-7.

43.  Lapouge K, Perozzo R, Iwaszkiewicz J, Bertelli C, Zoete V, Michielin O, et al. RNA pentaloop structures as effective targets of regulators belonging to the RsmA/CsrA protein family. RNA Biol. 2013;10(6):1031-41.

44.  Ismail HM, Dorchies OM, Perozzo R, Strosova MK, Scapozza L, Ruegg UT. Inhibition of iPLA2 beta and of stretch-activated channels by doxorubicin alters dystrophic muscle function. Br J Pharmacol. 2013;169(7):1537-50.

45.  Ceccon M, Mologni L, Bisson W, Scapozza L, Gambacorti-Passerini C. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors. Mol Cancer Res. 2013;11(2):122-32.

46.  Belluti F, Perozzo R, Lauciello L, Colizzi F, Kostrewa D, Bisi A, et al. Design, synthesis, and biological and crystallographic evaluation of novel inhibitors of Plasmodium falciparum enoyl-ACP-reductase (PfFabI). J Med Chem. 2013;56(19):7516-26.

47.  Lovera S, Sutto L, Boubeva R, Scapozza L, Dolker N, Gervasio FL. The different flexibility of c-Src and c-Abl kinases regulates the accessibility of a druggable inactive conformation. J Am Chem Soc. 2012;134(5):2496-9.

48.  Kasimova AO, Pavan GM, Danani A, Mondon K, Cristiani A, Scapozza L, et al. Validation of a novel molecular dynamics simulation approach for lipophilic drug incorporation into polymer micelles. J Phys Chem B. 2012;116(14):4338-45.

49.  Kalia YN, Perozzo R, Scapozza L. The pharmaceutical biochemistry group: where pharmaceutical chemistry meets biology and drug delivery. Chimia (Aarau). 2012;66(5):313-9.

50.  Tartari CJ, Scapozza L, Gambacorti-Passerini C. The ALK gene, an attractive target for inhibitor development. Curr Top Med Chem. 2011;11(11):1406-19.

51.  Martic M, Pernot L, Westermaier Y, Perozzo R, Kraljevic TG, Kristafor S, et al. Synthesis, crystal structure, and in vitro biological evaluation of C-6 pyrimidine derivatives: new lead structures for monitoring gene expression in vivo. Nucleosides Nucleotides Nucleic Acids. 2011;30(4):293-315.

52.  Kuettel S, Greenwald J, Kostrewa D, Ahmed S, Scapozza L, Perozzo R. Crystal structures of T. b. rhodesiense adenosine kinase complexed with inhibitor and activator: implications for catalysis and hyperactivation. PLoS Negl Trop Dis. 2011;5(5):e1164.

53.  Kristafor S, Novakovic I, Gazivoda Kraljevic T, Kraljevic Pavelic S, Lucin P, Westermaier Y, et al. A new N-methyl thymine derivative comprising a dihydroxyisobutenyl unit as ligand for thymidine kinase of herpes simplex virus type 1 (HSV-1 TK). Bioorg Med Chem Lett. 2011;21(20):6161-5.

54.  Jaquet V, Marcoux J, Forest E, Leidal KG, McCormick S, Westermaier Y, et al. NADPH oxidase (NOX) isoforms are inhibited by celastrol with a dual mode of action. Br J Pharmacol. 2011;164(2b):507-20.

55.  Dubey S, Perozzo R, Scapozza L, Kalia YN. Noninvasive transdermal iontophoretic delivery of biologically active human basic fibroblast growth factor. Mol Pharm. 2011;8(4):1322-31.

56.  Cristiani A, Costa G, Cozza G, Meggio F, Scapozza L, Moro S. The role of the N-terminal domain in the regulation of the "constitutively active" conformation of protein kinase CK2alpha: insight from a molecular dynamics investigation. ChemMedChem. 2011;6(7):1207-16.

57.  Cristiani A, Brisotto N, Cedrati FC, Floris M, Scapozza L, Moro S. ClickMD: an intuitive web-oriented molecular dynamics platform. Future Med Chem. 2011;3(8):923-31.

58.  Campos-Olivas R, Marenchino M, Scapozza L, Gervasio FL. Backbone assignment of the tyrosine kinase Src catalytic domain in complex with imatinib. Biomol NMR Assign. 2011;5(2):221-4.

59.  af Gennas GB, Mologni L, Ahmed S, Rajaratnam M, Marin O, Lindholm N, et al. Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors. ChemMedChem. 2011;6(9):1680-92.

60.  Mologni L, Rostagno R, Brussolo S, Knowles PP, Kjaer S, Murray-Rust J, et al. Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010;18(4):1482-96.

61.  Colizzi F, Perozzo R, Scapozza L, Recanatini M, Cavalli A. Single-molecule pulling simulations can discern active from inactive enzyme inhibitors. J Am Chem Soc. 2010;132(21):7361-71.

62.  Salemi S, Yousefi S, Simon D, Schmid I, Moretti L, Scapozza L, et al. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome. Allergy. 2009;64(6):913-8.

63.  Kuettel S, Mosimann M, Maser P, Kaiser M, Brun R, Scapozza L, et al. Adenosine Kinase of T. b. Rhodesiense identified as the putative target of 4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl]morpholine using chemical proteomics. PLoS Negl Trop Dis. 2009;3(8):e506.

64.  Jaquet V, Scapozza L, Clark RA, Krause KH, Lambeth JD. Small-molecule NOX inhibitors: ROS-generating NADPH oxidases as therapeutic targets. Antioxid Redox Signal. 2009;11(10):2535-52.

65.  Tartari CJ, Gunby RH, Coluccia AM, Sottocornola R, Cimbro B, Scapozza L, et al. Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase. J Biol Chem. 2008;283(7):3743-50.

66.  Puttini M, Redaelli S, Moretti L, Brussolo S, Gunby RH, Mologni L, et al. Characterization of compound 584, an Abl kinase inhibitor with lasting effects. Haematologica. 2008;93(5):653-61.

67.  Conus S, Perozzo R, Reinheckel T, Peters C, Scapozza L, Yousefi S, et al. Caspase-8 is activated by cathepsin D initiating neutrophil apoptosis during the resolution of inflammation. J Exp Med. 2008;205(3):685-98.

68.  Bisson WH, Westera G, Schubiger PA, Scapozza L. Homology modeling and dynamics of the extracellular domain of rat and human neuronal nicotinic acetylcholine receptor subtypes alpha4beta2 and alpha7. J Mol Model. 2008;14(10):891-9.

69.  Limacher A, Glaser AG, Meier C, Schmid-Grendelmeier P, Zeller S, Scapozza L, et al. Cross-reactivity and 1.4-A crystal structure of Malassezia sympodialis thioredoxin (Mala s 13), a member of a new pan-allergen family. J Immunol. 2007;178(1):389-96.

70.  Kuettel S, Zambon A, Kaiser M, Brun R, Scapozza L, Perozzo R. Synthesis and evaluation of antiparasitic activities of new 4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl]morpholine derivatives. J Med Chem. 2007;50(23):5833-9.

71.  Iqbal J, Scapozza L, Folkers G, Muller CE. Development and validation of a capillary electrophoresis method for the characterization of herpes simplex virus type 1 (HSV-1) thymidine kinase substrates and inhibitors. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;846(1-2):281-90.

72.  Yousefi S, Perozzo R, Schmid I, Ziemiecki A, Schaffner T, Scapozza L, et al. Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. Nat Cell Biol. 2006;8(10):1124-32.

73.  Tasdemir D, Lack G, Brun R, Ruedi P, Scapozza L, Perozzo R. Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006;49(11):3345-53.

74.  Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006;66(23):11314-22.

75.  Mologni L, Sala E, Cazzaniga S, Rostagno R, Kuoni T, Puttini M, et al. Inhibition of RET tyrosine kinase by SU5416. J Mol Endocrinol. 2006;37(2):199-212.

76.  Limacher A, Kloer DP, Fluckiger S, Folkers G, Crameri R, Scapozza L. The crystal structure of Aspergillus fumigatus cyclophilin reveals 3D domain swapping of a central element. Structure. 2006;14(2):185-95.

77.  Lack G, Homberger-Zizzari E, Folkers G, Scapozza L, Perozzo R. Recombinant expression and biochemical characterization of the unique elongating beta-ketoacyl-acyl carrier protein synthase involved in fatty acid biosynthesis of Plasmodium falciparum using natural and artificial substrates. J Biol Chem. 2006;281(14):9538-46.

78.  Johayem A, Raic-Malic S, Lazzati K, Schubiger PA, Scapozza L, Ametamey SM. Synthesis and characterization of a C6 nucleoside analogue for the in vivo imaging of the gene expression of herpes simplex virus type-1 thymidine kinase (HSV1 TK). Chem Biodivers. 2006;3(3):274-83.

79.  Gunby RH, Ahmed S, Sottocornola R, Gasser M, Redaelli S, Mologni L, et al. Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling. J Med Chem. 2006;49(19):5759-68.

80.  Glaser AG, Limacher A, Fluckiger S, Scheynius A, Scapozza L, Crameri R. Analysis of the cross-reactivity and of the 1.5 A crystal structure of the Malassezia sympodialis Mala s 6 allergen, a member of the cyclophilin pan-allergen family. Biochem J. 2006;396(1):41-9.

81.  Birringer MS, Perozzo R, Kut E, Stillhart C, Surber W, Scapozza L, et al. High-level expression and purification of human thymidine kinase 1: quaternary structure, stability, and kinetics. Protein Expr Purif. 2006;47(2):506-15.

82.  Schibli R, Dumas C, Petrig J, Spadola L, Scapozza L, Garcia-Garayoa E, et al. Synthesis and in vitro characterization of organometallic rhenium and technetium glucose complexes against Glut 1 and hexokinase. Bioconjug Chem. 2005;16(1):105-12.

83.  Piazza RG, Magistroni V, Gasser M, Andreoni F, Galietta A, Scapozza L, et al. Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib. Leukemia. 2005;19(1):132-4.

84.  Lamerz J, Selle H, Scapozza L, Crameri R, Schulz-Knappe P, Mohring T, et al. Correlation-associated peptide networks of human cerebrospinal fluid. Proteomics. 2005;5(11):2789-98.

85.  Lamerz J, Crameri R, Scapozza L, Mohring T, Selle H, Zucht HD. Peptide sequence prediction supported by correlation-associated networks in human cerebrospinal fluid. Comb Chem High Throughput Screen. 2005;8(8):789-99.

86.  Kostrewa D, Winkler FK, Folkers G, Scapozza L, Perozzo R. The crystal structure of PfFabZ, the unique beta-hydroxyacyl-ACP dehydratase involved in fatty acid biosynthesis of Plasmodium falciparum. Protein Sci. 2005;14(6):1570-80.

87.  Gunby RH, Tartari CJ, Porchia F, Donella-Deana A, Scapozza L, Gambacorti-Passerini C. An enzyme-linked immunosorbent assay to screen for inhibitors of the oncogenic anaplastic lymphoma kinase. Haematologica. 2005;90(7):988-90.

88.  Grazioso G, Moretti L, Scapozza L, De Amici M, De Micheli C. Development of a three-dimensional model for the N-methyl-D-aspartate NR2A subunit. J Med Chem. 2005;48(17):5489-94.

89.  Gambacorti-Passerini C, Gasser M, Ahmed S, Assouline S, Scapozza L. Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies. Leukemia. 2005;19(7):1267-9.

90.  Donella-Deana A, Marin O, Cesaro L, Gunby RH, Ferrarese A, Coluccia AM, et al. Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity. Biochemistry. 2005;44(23):8533-42.

91.  Coluccia AM, Gunby RH, Tartari CJ, Scapozza L, Gambacorti-Passerini C, Passoni L. Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy. Expert Opin Ther Targets. 2005;9(3):515-32.

92.  Bisson WH, Scapozza L, Westera G, Mu L, Schubiger PA. Ligand selectivity for the acetylcholine binding site of the rat alpha4beta2 and alpha3beta4 nicotinic subtypes investigated by molecular docking. J Med Chem. 2005;48(16):5123-30.

93.  Birringer MS, Claus MT, Folkers G, Kloer DP, Schulz GE, Scapozza L. Structure of a type II thymidine kinase with bound dTTP. FEBS Lett. 2005;579(6):1376-82.

94.  Schelling P, Claus MT, Johner R, Marquez VE, Schulz GE, Scapozza L. Biochemical and structural characterization of (South)-methanocarbathymidine that specifically inhibits growth of herpes simplex virus type 1 thymidine kinase-transduced osteosarcoma cells. J Biol Chem. 2004;279(31):32832-8.

95.  Raic-Malic S, Johayem A, Ametamey SM, Batinac S, De Clercq E, Folkers G, et al. Synthesis, 18F-radiolabelling and biological evaluations of C-6 alkylated pyrimidine nucleoside analogues. Nucleosides Nucleotides Nucleic Acids. 2004;23(11):1707-21.

96.  Perozzo R, Folkers G, Scapozza L. Thermodynamics of protein-ligand interactions: history, presence, and future aspects. J Recept Signal Transduct Res. 2004;24(1-2):1-52.

97.  Cavalli A, Prota AE, Stehle T, Dermody TS, Recanatini M, Folkers G, et al. A molecular dynamics study of reovirus attachment protein sigma1 reveals conformational changes in sigma1 structure. Biophys J. 2004;86(6):3423-31.

98.  Spadola L, Novellino E, Folkers G, Scapozza L. Homology modelling and docking studies on Varicella Zoster Virus Thymidine kinase. Eur J Med Chem. 2003;38(4):413-9.

99.  Russ P, Schelling P, Scapozza L, Folkers G, Clercq ED, Marquez VE. Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine. J Med Chem. 2003;46(23):5045-54.

100. Prekupec S, Svedruzic D, Gazivoda T, Mrvos-Sermek D, Nagl A, Grdisa M, et al. Synthesis and biological evaluation of iodinated and fluorinated 9-(2-hydroxypropyl) and 9-(2-hydroxyethoxy)methyl purine nucleoside analogues. J Med Chem. 2003;46(26):5763-72.

101. Pospisil P, Ballmer P, Scapozza L, Folkers G. Tautomerism in computer-aided drug design. J Recept Signal Transduct Res. 2003;23(4):361-71.

102. Gerharz T, Reinelt S, Kaspar S, Scapozza L, Bott M. Identification of basic amino acid residues important for citrate binding by the periplasmic receptor domain of the sensor kinase CitA. Biochemistry. 2003;42(19):5917-24.

103. Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. 2003;4(2):75-85.

104. Pospisil P, Kuoni T, Scapozza L, Folkers G. Methodology and problems of protein-ligand docking: case study of dihydroorotate dehydrogenase, thymidine kinase, and phosphodiesterase 4. J Recept Signal Transduct Res. 2002;22(1-4):141-54.

105. Gambacorti-Passerini CB, Rossi F, Verga M, Ruchatz H, Gunby R, Frapolli R, et al. Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients. Blood Cells Mol Dis. 2002;28(3):361-72.

106. Fluckiger S, Scapozza L, Mayer C, Blaser K, Folkers G, Crameri R. Immunological and structural analysis of IgE-mediated cross-reactivity between manganese superoxide dismutases. Int Arch Allergy Immunol. 2002;128(4):292-303.

107. Fluckiger S, Mittl PR, Scapozza L, Fijten H, Folkers G, Grutter MG, et al. Comparison of the crystal structures of the human manganese superoxide dismutase and the homologous Aspergillus fumigatus allergen at 2-A resolution. J Immunol. 2002;168(3):1267-72.

108. Wurth C, Thomas RM, Folkers G, Scapozza L. Folding and self-assembly of herpes simplex virus type 1 thymidine kinase. J Mol Biol. 2001;313(3):657-70.

109. Wurth C, Kessler U, Vogt J, Schulz GE, Folkers G, Scapozza L. The effect of substrate binding on the conformation and structural stability of Herpes simplex virus type 1 thymidine kinase. Protein Sci. 2001;10(1):63-73.

110. Sulpizi M, Schelling P, Folkers G, Carloni P, Scapozza L. The rational of catalytic activity of herpes simplex virus thymidine kinase. a combined biochemical and quantum chemical study. J Biol Chem. 2001;276(24):21692-7.

111. Schelling P, Folkers G, Scapozza L. A spectrophotometric assay for quantitative determination of kcat of herpes simplex virus type 1 thymidine kinase substrates. Anal Biochem. 2001;295(1):82-7.

112. Cavalli A, Dezi C, Folkers G, Scapozza L, Recanatini M. Three-dimensional model of the cyclin-dependent kinase 1 (CDK1): Ab initio active site parameters for molecular dynamics studies of CDKS. Proteins. 2001;45(4):478-85.

113. Vogt J, Perozzo R, Pautsch A, Prota A, Schelling P, Pilger B, et al. Nucleoside binding site of herpes simplex type 1 thymidine kinase analyzed by X-ray crystallography. Proteins. 2000;41(4):545-53.

114. Prota A, Vogt J, Pilger B, Perozzo R, Wurth C, Marquez VE, et al. Kinetics and crystal structure of the wild-type and the engineered Y101F mutant of Herpes simplex virus type 1 thymidine kinase interacting with (North)-methanocarba-thymidine. Biochemistry. 2000;39(31):9597-603.

115. Perozzo R, Jelesarov I, Bosshard HR, Folkers G, Scapozza L. Compulsory order of substrate binding to herpes simplex virus type 1 thymidine kinase. A calorimetric study. J Biol Chem. 2000;275(21):16139-45.

116. Amrhein I, Wurth C, Bohner T, Hofbauer R, Folkers G, Scapozza L. Highly purified recombinant varicella Zoster virus thymidine kinase is a homodimer. Protein Expr Purif. 2000;18(3):338-45.

117. Tasdemir D, Scapozza L, Zerbe O, Linden A, Calis I, Sticher O. Iridoid glycosides of Leonurus persicus. J Nat Prod. 1999;62(6):811-6.

118. Pilger BD, Perozzo R, Alber F, Wurth C, Folkers G, Scapozza L. Substrate diversity of herpes simplex virus thymidine kinase. Impact Of the kinematics of the enzyme. J Biol Chem. 1999;274(45):31967-73.

119. Kussmann-Gerber S, Wurth C, Scapozza L, Pilger BD, Pliska V, Folkers G. Interaction of the recombinant herpes simplex virus type 1 thymidine kinase with thymidine and aciclovir: a kinetic study. Nucleosides Nucleotides. 1999;18(3):311-30.

120. Kaspar S, Perozzo R, Reinelt S, Meyer M, Pfister K, Scapozza L, et al. The periplasmic domain of the histidine autokinase CitA functions as a highly specific citrate receptor. Mol Microbiol. 1999;33(4):858-72.

121. Christians FC, Scapozza L, Crameri A, Folkers G, Stemmer WP. Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling. Nat Biotechnol. 1999;17(3):259-64.

122. Kussmann-Gerber S, Kuonen O, Folkers G, Pilger BD, Scapozza L. Drug resistance of herpes simplex virus type 1--structural considerations at the molecular level of the thymidine kinase. Eur J Biochem. 1998;255(2):472-81.

123. Alber F, Kuonen O, Scapozza L, Folkers G, Carloni P. Density functional studies on herpes simplex virus type 1 thymidine kinase-substrate interactions: the role of Tyr-172 and Met-128 in thymine fixation. Proteins. 1998;31(4):453-9.

124. Rist B, Ingenhoven N, Scapozza L, Schnorrenberg G, Gaida W, Wieland HA, et al. The bioactive conformation of neuropeptide Y analogues at the human Y2-receptor. Eur J Biochem. 1997;247(3):1019-28.

125. Folkers G, Alber F, Amrhein I, Behrends H, Bohner T, Gerber S, et al. Integrated homology modelling and X-ray study of herpes simplex virus I thymidine kinase: a case study. J Recept Signal Transduct Res. 1997;17(1-3):475-94.

126. Rist B, Zerbe O, Ingenhoven N, Scapozza L, Peers C, Vaughan PF, et al. Modified, cyclic dodecapeptide analog of neuropeptide Y is the smallest full agonist at the human Y2 receptor. FEBS Lett. 1996;394(2):169-73.

127. Cunin R, Wales ME, Van Vliet F, De Staercke C, Scapozza L, Rani CS, et al. Allosteric regulation in a family of enterobacterial aspartate transcarbamylases: intramolecular transmission of regulatory signals in chimeric enzymes. J Mol Biol. 1996;262(2):258-69.

128. Botos I, Scapozza L, Zhang D, Liotta LA, Meyer EF. Batimastat, a potent matrix mealloproteinase inhibitor, exhibits an unexpected mode of binding. Proc Natl Acad Sci U S A. 1996;93(7):2749-54.

129. Scapozza L, Rognan D, Folkers G, Daser A. Molecular dynamics and structure-based drug design for predicting non-natural nonapeptide binding to a class I MHC protein. Acta Crystallogr D Biol Crystallogr. 1995;51(Pt 4):541-9.

130. Rognan D, Scapozza L, Folkers G, Daser A. Rational design of nonnatural peptides as high-affinity ligands for the HLA-B*2705 human leukocyte antigen. Proc Natl Acad Sci U S A. 1995;92(3):753-7.

131. Botos I, Scapozza L, Shannon JD, Fox JW, Meyer EF. Structure-based analysis of inhibitor binding to Ht-d. Acta Crystallogr D Biol Crystallogr. 1995;51(Pt 4):597-604.

132. Rognan D, Scapozza L, Folkers G, Daser A. Molecular dynamics simulation of MHC-peptide complexes as a tool for predicting potential T cell epitopes. Biochemistry. 1994;33(38):11476-85.

133. Joshi RK, Meister T, Scapozza L, Ha TK. A new quantum chemical approach in QSAR-analysis. Parametrisation of conformational energies into molecular descriptors JMn (steric) and JSn (electronic). Arzneimittelforschung. 1994;44(6):779-90.